Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Capital Expenditures (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Capital Expenditures for 16 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 1115.28% year-over-year to -$2.9 million, compared with a TTM value of $73000.0 through Dec 2025, down 97.95%, and an annual FY2025 reading of $73000.0, down 97.95% over the prior year.
  • Capital Expenditures was -$2.9 million for Q4 2025 at Amicus Therapeutics, down from $382000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6.6 million in Q4 2023 and bottomed at -$3.3 million in Q3 2023.
  • Average Capital Expenditures over 5 years is $804550.0, with a median of $374000.0 recorded in 2021.
  • Peak annual rise in Capital Expenditures hit 12521.15% in 2023, while the deepest fall reached 2284.67% in 2023.
  • Year by year, Capital Expenditures stood at $3.6 million in 2021, then tumbled by 98.54% to $52000.0 in 2022, then surged by 12521.15% to $6.6 million in 2023, then plummeted by 95.61% to $288000.0 in 2024, then crashed by 1115.28% to -$2.9 million in 2025.
  • Business Quant data shows Capital Expenditures for FOLD at -$2.9 million in Q4 2025, $382000.0 in Q3 2025, and $2.4 million in Q2 2025.